Citius Pharmaceuticals, Inc. short interest in 2026
In 2026, Citius Pharmaceuticals, Inc.'s disclosed short interest ran from 14.08% of shares outstanding on 15 Jan 2026 to 20.26% on 15 Sep 2026, a change of +6.18 percentage points. The year's high was 25.35% on 30 Apr 2026 and its low 13.10% on 30 Jan 2026, averaging 18.27% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.48 days on 15 Sep 2026. Full history: Citius Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 14.08% (15 Jan 2026)
- End of year
- 20.26% (15 Sep 2026)
- Change
- +6.18 pp
- High
- 25.35% (30 Apr 2026)
- Low
- 13.10% (30 Jan 2026)
- Average
- 18.27%
- Highest days to cover
- 27.48 (15 Sep 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 14.08% | 9.96 | |
| 30 Jan 2026 | 13.10% | 9.91 | |
| 13 Feb 2026 | 15.07% | 4.39 | 10-Q filed, results (8-K) |
| 27 Feb 2026 | 16.10% | 11.60 | |
| 13 Mar 2026 | 19.48% | 3.61 | |
| 31 Mar 2026 | 18.81% | 6.86 | |
| 15 Apr 2026 | 19.29% | 13.69 | |
| 30 Apr 2026 | 25.35% | 4.28 | |
| 15 May 2026 | 18.81% | 6.82 | 10-Q filed, results (8-K) |
| 29 May 2026 | 18.02% | 5.52 | |
| 15 Jun 2026 | 17.79% | 14.73 | |
| 30 Jun 2026 | 17.35% | 23.44 | |
| 15 Jul 2026 | 18.15% | 26.04 | |
| 31 Jul 2026 | 18.79% | 8.25 | |
| 14 Aug 2026 | 19.55% | 5.32 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 20.51% | 6.06 | |
| 15 Sep 2026 | 20.26% | 27.48 |
See also: Citius Pharmaceuticals, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.